

SUMMARY OF PRODUCT CHARACTERISTICS

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

XYLAPAN 20mg solution for injection

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Each ml contains:

Active substance

Xylazine Hydrochloride (equivalent to Xylazine)	23.32 mg
	20.0 mg

Excipients

Parahydroxybenzoate (E218)	0.65 mg
Parahydroxybenzoate (E216)	0.35 mg
As preservatives.	

For a full list of excipients, see section 6.1

3. PHARMACEUTICAL FORM

Solution for injection.
Clear colourless aqueous sterile solution

4. CLINICAL PARTICULARS

4.1 Target species

Horses, cattle, dogs and cats.

4.2 Indications for use, specifying the target species

Used in all cases where sedation is required. The main indications for use include the following:

- General handling and transport of nervous or fractious animals.
- Medical examinations and treatment such as X-rays, oral, genital and rectal examination.
- Premedication for minor surgical interventions and for anaesthesia in combination with other analgesics, narcotics and inhalant anaesthetics.

4.3 Contra-indications

Not for use in the latter stages of pregnancy except at parturition.

Because of the emetic effect which is sometimes produced, the product should not be used in cats and dogs with mechanical complications of the alimentary tract such as obstruction of the oesophagus, gastric torsion, or hernia.

4.4 Special warnings for each target species

Horse

Following intravenous injection there is a transient rise followed by a fall of blood pressure.

The usual precautions required for handling should always be observed even when a high dose of xylazine is given.

Cattle

In recumbent cattle tympany should be prevented by maintaining sternal recumbency.

For operations in lateral or dorsal recumbency it is advisable to lower the head and neck in order to avoid inhalation of saliva or ruminal fluids. When high doses are to be employed the animal should be fasted for some hours beforehand.

After dose level 3 & 4, cattle are likely to remain drowsy for several hours and should be kept in the shade.

4.5 Special precautions for use

i. Special precautions for use in animals

As safety of xylazine use during organogenesis has not been proven by current methods, care should be taken during the first month of pregnancy.

Care should be taken with aged animals or those with compromised lung function or suspected pulmonary disease since xylazine will depress respiration.

In the event of respiratory failure, manual compression of the thorax is usually sufficient to restore normal respiration.

Calm, old, sick animals react more distinctly to the product.

Sedated animals should be kept under supervision until normal, and they should be segregated to avoid bullying by others.

ii. Special precautions to be taken by the person administering the veterinary medicinal product to animals

Care should be taken to avoid accidental self-injection. To avoid accidental self-injection, one of the following procedures should be adopted. Either use two sterile needles, one to fill syringe from bottle and one to inject patient, or once the required dose has been withdrawn from the vial, immediately remove the needle from the syringe, insert the needle into the injection site, and then connect the syringe to it. Used needles should be safely deposited in a closed container.

1. In the case of accidental oral intake or self-injection, seek medical advice immediately and show the package leaflet to the doctor but DO NOT DRIVE as sedation and changes in blood pressure may occur.
2. Avoid skin, eye or mucosal contact.
3. Immediately after exposure, wash the exposed skin with large amounts of fresh water.
4. Remove contaminated clothes that are in direct contact with skin.
5. In the case of accidental contact of the product with eyes, rinse with large amounts of fresh water. If symptoms occur, seek the advice of a doctor.
6. If pregnant women handle the product, special caution should be observed not to self-inject as uterine contractions and decreased foetal blood pressure may occur after accidental systemic exposure.
7. Advice to doctors:

Xylazine is an alpha2-adrenoceptor agonist. Symptoms after absorption may involve clinical effects including dose-dependent sedation, respiratory depression, bradycardia, hypotension, a dry mouth, and hyperglycaemia. Ventricular arrhythmias have also been reported. Respiratory and haemodynamic symptoms should be treated symptomatically.

4.6 Adverse reactions (frequency and seriousness)

Transient hyperglycaemia is a common finding after administration

Horses

Following intravenous injection there is a transient rise followed by a fall of blood pressure.

Cattle

The swallowing reflex is reduced during the period when the action of the drug is at its peak.

Cats and dogs

If the stomach is full, vomiting occurs before sedation is complete. This is an advantage if general anaesthesia is to follow. The emetic effect is reduced by fasting for 6-24 hours before administration..

4.7 Use during pregnancy, lactation or lay

The product is contraindicated for use at the latter stages of pregnancy except at parturition.

4.8 Interaction with other medicinal products and other forms of interaction

Analeptics (stimulants) will shorten the period or reduce the depth of sedation. In horses and dogs a deeper sedation with less side effects is achieved when Xylazine is combined with strong analgesics.

Horses

The concurrent intravenous use of potentiated sulphonamides with alpha-2 agonists has been reported to cause cardiac arrhythmia which may be fatal. It is recommended that intravenous administration of trimethoprim/sulphonamide containing products should not be undertaken when horses have been sedated with the product.

Limited information available indicates that alpha-2 blockers such as atipamazole may be effective in reversing the sedation and other physiological effects of the drug.

4.9 Amounts to be administered and administration route

Syringes and needles must be sterile. Clean area of injection site and swab with spirit.

It should be noted that dosage and routes of administration vary widely between species.

An appropriately graduated syringe must be used to allow accurate administration of the required dose volume. This is particularly important when injecting small volumes.

Cattle

Administer by intramuscular injection.

The dose rate is 0.05-0.3 mg/kg b.w. (0.25 – 1.5 ml/100 kg b.w.), according to the degree of sedation required. Very fractious animals may require the higher dose rates not exceeding 0.3 mg/kg b.w., (Dose rate 4).

Dose	mg/kg	mg/50 kg	ml/50 kg
1	0.05	2.5	0.125
2	0.10	5.0	0.25
3	0.20	10.0	0.50
4	0.30	15.0	0.75

The degree of sedation can be predetermined according to the dose administered:

Dose 1: Sedation, with a slight decrease of muscle tone. The ability to stand is maintained.

Dose 2: Sedation, marked decrease of muscle tone and some analgesia. The animal usually remains standing, but may lie down.

Dose 3: Deep sedation, further decrease of muscle tone and a degree of analgesia. The animal lies down.

Dose 4: Very deep sedation, a profound decrease in muscle tone and a degree of analgesia. The animal lies down.

After doses 3 and 4 cattle are likely to remain drowsy for several hours and should be kept in the shade.

Animals should not be disturbed until Xylazine has taken its full effect. The first effects are usually seen within 5 minutes of injection and the maximum effect is produced ten minutes later. There is no struggling or excitement during induction or recovery.

If the required depth of sedation is not achieved it is unlikely that repetition of the dose will prove more effective. Repeating the procedure with a higher dose after 24 hours is recommended.

For any surgical treatment additional local anaesthesia should be employed.

Horses

Administer by slow intravenous injection, taking from one to two minutes. The dose rate is 0.6 – 1 mg/kg b.w. (3-5 ml/100 kg b.w.) according to the degree of sedation required and the response of the animal.

Depending on the dosage, light to deep sedation with individually variable analgesia is obtained. The horse does not become recumbent.

Nervous or highly excitable animals generally require the higher dose.

Older horses and those that have undergone severe physical exertion before treatment respond more readily to Xylazine.

Animals should not be disturbed until the product has taken its full effect. This is usually within five minutes of intravenous injection and lasts for approximately 20 minutes.

If the required depth of sedation is not achieved it is unlikely that repetition of the dose will prove more effective. Repeating the procedure with a higher dose after 24 hours is recommended.

For painful operations, additional local or regional anaesthesia should be used.

The product can also be administered to horses as premedication for operations on the recumbent animal using chloral hydrate, barbiturates, ketamine or halothane.

Cats

Administer intramuscularly at a dose rate of 3 mg/kg b.w. (0.15 ml/kg b.w.). The effect is adequate for procedures that are not associated with any considerable degree of pain. Premedication with atropine is advantageous. When used in conjunction with ketamine, xylazine premedication eliminates muscular stiffness during anaesthesia and maintains sedation throughout the recovery period. Barbiturate anaesthesia should not be induced until sedation is at its deepest, i.e. about 20 minutes after administration of xylazine. Under these conditions the dose of barbiturates is reduced by about half.

Dogs

Administer intramuscularly at a dose rate of 1-3 mg/kg b.w. (0.05-0.15 ml/kg b.w.). Other routes of administration may be used, but the effect is less predictable. Good sedation is usually achieved at the lower end of the dose range given above, but excitable or vicious animals require a higher dose. The effect is adequate for procedures that are not associated with any considerable degree of pain. For painful procedures the product may be used in combination with a local anaesthetic.

Premedication with atropine may be advantageous.

When used for pre-anaesthetic medication, xylazine reduces the dose required in the case of barbiturates by about half.

The product can also be used as a premedicant for ketamine induced anaesthesia.

4.10 Overdose (symptoms, emergency procedures, antidotes), if necessary

In case of accidental overdose leading to respiratory failure, cold water douches and artificial respiration are indicated.

4.11 Withdrawal period(s)

Meat and offal:

Cattle: One day

Horses: One day

Milk: Zero hours

5. PHARMACOLOGICAL PROPERTIES

Xylazine is an alpha-2 adrenergic agonist with sedative, analgesic and muscle relaxant properties. In cattle the degree of sedation can be predetermined according to the dose administered.

ATC vet code: QN05CM92

6. PHARMACEUTICAL PARTICULARS

6.1 List of excipients

Methyl Hydroxybenzoate
Propyl Hydroxybenzoate
Sodium Chloride
Water for Injections

6.2 Incompatibilities

None known.

6.3 Shelf life

Shelf life of the veterinary medicinal product as packaged for sale: 4 years

Shelf life after first opening the immediate packaging: 12 days.

6.4. Special precautions for storage

Do not store above 25°C

Following withdrawal of the first dose, use the product within 12 days. Discard unused material. Avoid introduction of contamination.

6.5 Nature and composition of immediate packaging

Clear glass vials, Type I, with rubber stoppers and aluminium caps, containing 10 and 50 ml of solution.

Not all pack sizes may be marketed.

6.6 Special precautions for the disposal of unused veterinary medicinal product or waste materials derived from the use of such products

Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal products should be disposed of in accordance with local requirements.

7. MARKETING AUTHORISATION HOLDER

Vetoquinol UK Limited
Steadings Barn
Pury Hill Business Park
Nr. Alderton
Towcester
Northamptonshire
NN12 7LS

8. MARKETING AUTHORISATION NUMBER

Vm 08007/5051

9. DATE OF FIRST AUTHORISATION

22 December 1999

10. DATE OF REVISION OF THE TEXT

December 2025

Gavin Hall
Approved: 05 December 2025